1416134-58-1

Basic information

• Product Name: ethyl (S)-2-((tert-butoxycarbonyl)amino)-6-(dimethyl(oxo)-λ⁶-sulfanylidene)-5-oxohexanoate
• Synonyms: ethyl (S)-2-((tert-butoxycarbonyl)amino)-6-(dimethyl(oxo)-λ⁶-sulfanylidene)-5-oxohexanoate
• CAS NO: 1416134-58-1
• Molecular Weight: 349.448
• Mol File: 1416134-58-1.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: ethyl (S)-2-((tert-butoxycarbonyl)amino)-6-(dimethyl(oxo)-λ⁶-sulfanylidene)-5-oxohexanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl (S)-2-((tert-butoxycarbonyl)amino)-6-(dimethyl(oxo)-λ⁶-sulfanylidene)-5-oxohexanoate(1416134-58-1)
• EPA Substance Registry System: ethyl (S)-2-((tert-butoxycarbonyl)amino)-6-(dimethyl(oxo)-λ⁶-sulfanylidene)-5-oxohexanoate(1416134-58-1)

Safety Data

• Hazardous Substances Data: 1416134-58-1(Hazardous Substances Data)

Upstream product

• 1774-47-6 trimethylsulfoxonium iodide 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 67-68-5 dimethyl sulfoxide 

Downstream Products

• 1416134-59-2 C₂₀H₂₉ClN₂O₅ 
• 1192500-31-4 (2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicylco[3.2.1]octan-6-yl hydrogensulfate 
• 1192651-49-2 (1R,2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide 
• 1192491-61-4 (2S,5R)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide 7-oxo-6-(sulfoxy)monosodium salt 
• 1416134-49-0 (2S,5R)-5-(benzyloxyamino)-piperidine-2-carboxylic acid amide 
• 1192651-80-1 ({[(2S,5R)-2-carbamoyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3,2,1]-oct-6-yl]oxy}sulfonyl)tetrabutylammonium salt 
• 1416134-48-9 ethyl (2S,5R)-5-[(benzyloxy)amino]piperidine-2-carboxylate oxalic acid salt 
• 1416134-60-5 5-benzyloxyiminopiperidine-2S-carboxylic acid ethyl ester 
• 1416134-63-8 (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octan-2-carboxylic acid ethyl ester 
• 1471297-48-9 (3R,6S)-6-(1,2,4-oxadiazol-3-yl)piperidin-3-yl(benzyloxy)carbamic chloride 
• 1471297-50-3 (2S,5R)-6-(benzyloxy)-2-(1,2,4-oxadiazol-3-yl)-1,6-diazabicyclo[3.2.1]octan-7-one 
• 1471297-60-5 (2S,5R)-2-(5-amino-1,2,4-oxadiazol-3-yl)-6-(benzyloxy)-1,6-diazabicyclo[3.2.1]octan-7-one 
• 1471297-71-8 (2S,5R)-tert-butyl 2-(5-(1-(((9H-fluoren-9-yl)methoxy)carbonyl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)-5-(benzyloxyamino)piperidine-1-carboxylate 
• 1471297-75-2 (9H-fluoren-9-yl)methyl 4-(3-((2S,5R)-5-(benzyloxy(chlorocarbonyl)amino)piperidin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate 

Relevant articles and documents

Synthetic method of avibactam intermediate (2S,5S)-N-protective group-5-hydroxy-2-piperidine formate

The invention discloses a synthetic method of an avibactam intermediate (2S,5S)-N-protective group-5-hydroxy-2-piperidine formate. N-protective group-L-pyroglutamate (SM) is taken as an initial raw material, and the (2S,5S)-N-protective group-5-hydroxy-2-piperidine formate is obtained through six steps of reactions including trimethyl sulfoxide iodide recarburization ring opening, halogenation under the action of acid, high-selectivity reduction, lactone ring formation under the catalysis of acid, piperidine ring closing under the action of alkali and hydrolysis. The synthetic method is mild in reaction conditions, simple and convenient to operate, easy in impurity control and stable in yield. The used reagents are low in price, the cost is effectively reduced, and the method is environment-friendly and suitable for industrial production.

B-LACTAMASE INHIBITOR AND APPLICATION THEREOF

The present invention relates to a compound of Formula (I)-(IV) useful as β-lactamase inhibitor, a pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof, wherein R1, R2, M and ring A have definitions as those in the specification. The present invention further relates to methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and uses of these compounds. For example, the compounds of the present invention can be used as β-lactamase inhibitors, for treatment and/or prophylaxis of diseases caused by bacterial infections, solving drug-resistance problems caused by β-lactamases, especially bacterial drug-resistant diseases caused by type B metallo-β-lactamases.

CRYSTALLINE FORM OF A BETA-LACTAMASE INHIBITOR

This disclosure provides compositions containing solid forms of sodium (2S,5R)-2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate, and methods of manufacturing and using these compositions.